Histiocytoma: Clinical Trials

57 trials for Histiocytoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 8 unknown, 7 recruiting, 5 terminated. 57 Phase 2, 9 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 257Completed 29, Unknown 8, Recruiting 7, Terminated 5, Active not recruiting 4, Not yet recruiting 2, Withdrawn 2
Phase 19Completed 6, Terminated 2, Unknown 1
Phase 32Completed 1, Terminated 1

Follow Histiocytoma: new trials by email Literature Review of Histiocytoma trials Research Report on Histiocytoma

Trials (filtered) newest first · largest first

All 57 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
DT-7012, Doxorubicin - Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
Phase 2Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris802027-02-012026-09-15
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS)
Phase 2RecruitingIovance Biotherapeutics, Inc.802026-10-022026-10-09
SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma
Toripalimab, Liposomal doxorubicin, Stereotactic body radiotherapy (SBRT) - Undifferentiated Pleomorphic Sarcoma (UPS)
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital392026-09-012026-09-14
Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult
Phase 2RecruitingOslo University Hospital402026-01-262026-01-28
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult
Phase 2RecruitingOslo University Hospital1102026-01-262026-01-28
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma
Phase 2RecruitingHRYZ Biotech Co.1482024-02-212025-07-24
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
Biopsy Procedure, Biospecimen Collection, Cabozantinib - Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma
Phase 2Active not recruitingNational Cancer Institute LAO662023-10-252026-10-09
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Association of pembrolizumab + cabozantinib - Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma
Phase 2RecruitingInstitut BergoniƩ1192022-04-252025-10-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma
Phase 2WithdrawnBrown University2022-03-012021-12-07
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma
Phase 2WithdrawnBrown University2021-09-012021-07-28
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma
Phase 2RecruitingNiels Junker802021-08-172023-07-27
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
Sintilimab - Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Phase 2TerminatedM.D. Anderson Cancer Center62021-07-132024-12-11
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Phase 2UnknownTracon Pharmaceuticals Inc.2072020-12-092024-05-17
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma
Phase 2RecruitingMemorial Sloan Kettering Cancer Center302020-04-012026-04-23
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma
Phase 2Active not recruitingNational Cancer Institute (NCI)402019-12-312026-11-12
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
Anlotinib, Toripalimab, Blood Draw - Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Phase 2UnknownDi Wu252019-07-192019-07-10
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Eribulin, Pembrolizumab - Sarcoma, Liposarcoma
Phase 2CompletedDana-Farber Cancer Institute572019-06-042025-08-28
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma
Phase 2UnknownMaria Sklodowska-Curie National Research Institute of Oncology302018-06-012021-02-01
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma
Phase 2Active not recruitingM.D. Anderson Cancer Center302018-04-272026-11-10
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Phase 1 / Phase 2CompletedBioAtla, Inc.2452018-02-152025-09-23

Showing 20 of 57. Sign in to see all of them.

Narrower conditions

Histiocytoma, Malignant Fibrous (54)  ·  Sarcoma (48)  ·  Leiomyosarcoma (38)  ·  Liposarcoma (34)  ·  Sarcoma, Synovial (31)  ·  Fibrosarcoma (27)  ·  Neurofibrosarcoma (25)  ·  Hemangiosarcoma (23)  ·  Rhabdomyosarcoma (20)  ·  Dermatofibrosarcoma (17)  ·  Sarcoma, Alveolar Soft Part (17)  ·  Hemangiopericytoma, Malignant (11)  ·  Osteosarcoma (11)  ·  Malignant mesenchymal tumor (10)  ·  Chondrosarcoma, Extraskeletal Myxoid (9)

Broader conditions

Neoplasms by Histologic Type (57)  ·  Neoplasms, Connective Tissue (57)  ·  Neoplasms, Fibrous Tissue (57)  ·  Neoplasms, Connective and Soft Tissue (56)  ·  Neoplasms (54)  ·  Neoplasms, Muscle Tissue (41)  ·  Neoplasms, Adipose Tissue (34)  ·  Neoplasms, Nerve Tissue (27)  ·  Nervous System Diseases (26)  ·  Nervous System Neoplasms (26)  ·  Neurofibroma (25)  ·  Neuromuscular Diseases (25)  ·  Peripheral Nervous System Diseases (25)  ·  Peripheral Nervous System Neoplasms (25)

Interventions

Doxorubicin (8)  ·  Radiotherapy (6)  ·  Ipilimumab (5)  ·  Nivolumab (5)  ·  CTLA-4 Antigen (4)  ·  Docetaxel (4)  ·  Gemcitabine (4)  ·  Ifosfamide (4)  ·  pazopanib (4)  ·  Bevacizumab (3)  ·  Radiation (3)  ·  Sunitinib (3)  ·  pembrolizumab (3)  ·  3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2)  ·  Biopsy (2)

Sponsors

National Cancer Institute (NCI) (9)  ·  European Organisation for Research and Treatment of Cancer - EORTC (8)  ·  M.D. Anderson Cancer Center (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Brown University (2)  ·  Maria Sklodowska-Curie National Research Institute of Oncology (2)  ·  Oslo University Hospital (2)  ·  BioAtla, Inc. (1)  ·  Celgene (1)  ·  City of Hope Medical Center (1)  ·  Daiichi Sankyo (1)  ·  Dana-Farber Cancer Institute (1)  ·  Di Wu (1)  ·  Grupo Espanol de Investigacion en Sarcomas (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)

Countries

United States (35)  ·  France (7)  ·  United Kingdom (7)  ·  Belgium (6)  ·  Canada (6)  ·  Netherlands (5)  ·  Denmark (4)  ·  China (3)  ·  Germany (3)  ·  Norway (3)  ·  Poland (3)  ·  Spain (3)  ·  Switzerland (3)  ·  Italy (2)  ·  Puerto Rico (2)

Top investigators

Ivar Hompland, MD, PhD (2)  ·  Kjetil Boye, MD, PhD (2)  ·  William Tap, MD (2)  ·  A P Chen (1)  ·  Aaron R Weiss (1)  ·  Alba Rubio (1)  ·  Alberto Chiappori, M.D. (1)  ·  Allan T. van Oosterom, MD, PhD (1)  ·  Amir A Jazaeri (1)  ·  Antonio Casado (1)  ·  Axel Le Cesne, MD (1)  ·  Bradley D DeNardo, MD (1)

Results publications

PMID 31401903, PMID 32827353, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20471824, PMID 20932656, PMID 23382028, PMID 24215845, PMID 24637635, PMID 27502708, PMID 29370992, PMID 30249211, PMID 30410720, PMID 32554315, PMID 32702309, PMID 33203665, PMID 34515544, PMID 34722269, PMID 35115306, PMID 35934010, PMID 37523624, PMID 38236580, PMID 38579194, PMID 39343511, PMID 39356980, PMID 41836677, PMID 42194972

NIH funding

P30CA008748 (3), U10CA180821 (3), N01CM62206 (2), 2009 (1), N01CM62201 (1), N01CM62203 (1), P30CA012197 (1), P30CA033572 (1), R21CA117128 (1), U01CA069856 (1), U10CA031946 (1), U10CA081851 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)